Advanced search
Publication Cover
Future Medicinal Chemistry Volume 5, 2013 - Issue 2
Submit an article Journal homepage
121
Views
0
CrossRef citations to date
0
Altmetric
Review

Therapeutic Potential of Targeting Lipid Aldehydes and Lipoxidation End-Products in the Treatment of Ocular Disease

Rosemary E McDowellCentre for Vision & Vascular Science, Queen’s University of Belfast, Institute of Clinical Sciences, The Royal Victoria Hospital, Grosvenor Road, BelfastBT12 6BA, Northern Ireland, UKView further author information
,
J Graham McGeownCentre for Vision & Vascular Science, Queen’s University of Belfast, Institute of Clinical Sciences, The Royal Victoria Hospital, Grosvenor Road, BelfastBT12 6BA, Northern Ireland, UKView further author information
,
Alan W StittCentre for Vision & Vascular Science, Queen’s University of Belfast, Institute of Clinical Sciences, The Royal Victoria Hospital, Grosvenor Road, BelfastBT12 6BA, Northern Ireland, UKView further author information
&
Tim M CurtisCentre for Vision & Vascular Science, Queen’s University of Belfast, Institute of Clinical Sciences, The Royal Victoria Hospital, Grosvenor Road, BelfastBT12 6BA, Northern Ireland, UKCorrespondence[email protected]
View further author information
Pages 189-211 | Published online: 30 Jan 2013

References

  • Barnham KJ , MastersCL, BushAI. Neurodegenerative diseases and oxidative stress.Nat. Rev. Drug Discov.3(3), 205–214 (2004).
  • Griendling KK , FitzGeraldGA. Oxidative stress and cardiovascular injury. Part II: animal and human studies.Circulation108(17), 2034–2040 (2003).
  • Aldini G , le-DonneI, FacinoRM, MilzaniA, CariniM. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls.Med. Res. Rev.27(6), 817–868 (2007).
  • Negre-Salvayre A , CoatrieuxC, IngueneauC, SalvayreR. Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.Br. J. Pharmacol.153(1), 6–20 (2008).
  • Esterbauer H , SchaurRJ, ZollnerH. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.Free Radic. Biol. Med.11(1), 81–128 (1991).
  • Uchida K . Current status of acrolein as a lipid peroxidation product.Trends Cardiovasc. Med.9(5), 109–113 (1999).
  • Catala A . Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions.Chem. Phys. Lipids157(1), 1–11 (2009).
  • Pamplona R . Advanced lipoxidation end-products.Chem. Biol. Interact.192(1–2), 14–20 (2011).
  • Esterbauer H . Cytotoxicity and genotoxicity of lipid-oxidation products.Am. J. Clin. Nutr.57(5 Suppl.), 779S–785S (1993).
  • Petersen DR , DoornJA. Reactions of 4-hydroxynonenal with proteins and cellular targets.Free Radic. Biol. Med.37(7), 937–945 (2004).
  • Uchida K , StadtmanER. Modification of histidine residues in proteins by reaction with 4-hydroxynonenal.Proc. Natl Acad. Sci. USA89(10), 4544–4548 (1992).
  • Nadkarni DV , SayreLM. Structural definition of early lysine and histidine adduction chemistry of 4-hydroxynonenal.Chem. Res. Toxicol.8(2), 284–291 (1995).
  • Long EK , PickloMJ Sr. Trans-4-hydroxy-2-hexenal, a product of n-3 fatty acid peroxidation: make some room HNE. Free Radic. Biol. Med.49(1), 1–8 (2010).
  • Long EK , MurphyTC, LeiphonLJet al. Trans-4-hydroxy-2-hexenal is a neurotoxic product of docosahexaenoic (22:6; n-3) acid oxidation. J. Neurochem. 105(3), 714–724 (2008).
  • Riahi Y , CohenG, ShamniO, SassonS. Signaling and cytotoxic functions of 4-hydroxyalkenals.Am. J. Physiol. Endocrinol. Metab299(6), E879–E886 (2010).
  • Kaneko T , KajiK, MatsuoM. Cytotoxicities of a linoleic acid hydroperoxide and its related aliphatic aldehydes toward cultured human umbilical vein endothelial cells.Chem. Biol. Interact.67(3–4), 295–304 (1988).
  • Aldini G , OrioliM, CariniM. Protein modification by acrolein: relevance to pathological conditions and inhibition by aldehyde sequestering agents.Mol. Nutr. Food Res.55(9), 1301–1319 (2011).
  • Uchida K , KanematsuM, MorimitsuY, OsawaT, NoguchiN, NikiE. Acrolein is a product of lipid peroxidation reaction. Formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins.J. Biol. Chem.273(26), 16058–16066 (1998).
  • Stevens JF , MaierCS. Acrolein: sources, metabolism, and biomolecular interactions relevant to human health and disease.Mol. Nutr. Food Res.52(1), 7–25 (2008).
  • Weiss SJ . Tissue destruction by neutrophils.N. Engl. J. Med.320(6), 365–376 (1989).
  • Anderson MM , HazenSL, HsuFF, HeineckeJW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest99(3), 424–432 (1997).
  • O‘Brien PJ , SirakiAG, ShangariN. Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health.Crit. Rev. Toxicol.35(7), 609–662 (2005).
  • Igarashi K , KashiwagiK. Protein-conjugated acrolein as a biochemical marker of brain infarction.Mol. Nutr. Food Res.55(9), 1332–1341 (2011).
  • Saiki R , NishimuraK, IshiiIet al. Intense correlation between brain infarction and protein-conjugated acrolein. Stroke 40(10), 3356–3361 (2009).
  • Cai J , BhatnagarA, PierceWM Jr. Protein modification by acrolein: formation and stability of cysteine adducts. Chem. Res. Toxicol.22(4), 708–716 (2009).
  • Maeshima T , HondaK, ChikazawaMet al. quantitative analysis of acrolein-specific adducts generated during lipid peroxidation-modification of proteins in vitro: identification of N(tau)-(3-propanal)histidine as the major adduct. Chem. Res. Toxicol. 25(7), 1384–1392 (2012).
  • Furuhata A , NakamuraM, OsawaT, UchidaK. Thiolation of protein-bound carcinogenic aldehyde. An electrophilic acrolein-lysine adduct that covalently binds to thiols.J. Biol. Chem.277(31), 27919–27926 (2002).
  • Furuhata A , IshiiT, KumazawaS, YamadaT, NakayamaT, UchidaK. N(epsilon)-(3-methylpyridinium)lysine, a major antigenic adduct generated in acrolein-modified protein. J. Biol. Chem.278(49), 48658–48665 (2003).
  • Choi J , LairdJM, SalomonRG. An efficient synthesis of gamma-hydroxy-alpha,beta-unsaturated aldehydic esters of 2-lysophosphatidylcholine.Bioorg. Med. Chem.19(1), 580–587 (2011).
  • Salomon RG , HongL, HollyfieldJG. Discovery of carboxyethylpyrroles (CEPs): critical insights into AMD, autism, cancer, and wound healing from basic research on the chemistry of oxidized phospholipids.Chem. Res. Toxicol.24(11), 1803–1816 (2011).
  • McGirr LG , HadleyM, DraperHH. Identification of N alpha-acetyl-epsilon-(2-propenal)lysine as a urinary metabolite of malondialdehyde. J. Biol. Chem.260(29), 15427–15431 (1985).
  • Uchida K , SakaiK, ItakuraK, OsawaT, ToyokuniS. Protein modification by lipid peroxidation products: formation of malondialdehyde-derived N(epsilon)-(2-propenol)lysine in proteins. Arch. Biochem. Biophys.346(1), 45–52 (1997).
  • Ishii T , KumazawaS, SakuraiT, NakayamaT, UchidaK. Mass spectroscopic characterization of protein modification by malondialdehyde.Chem. Res. Toxicol.19(1), 122–129 (2006).
  • Nair V , CooperCS, ViettiDE, TurnerGA. The chemistry of lipid peroxidation metabolites: crosslinking reactions of malondialdehyde.Lipids21(1), 6–10 (1986).
  • Reddy S , BichlerJ, Wells-KnechtKJ, ThorpeSR, BaynesJW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.Biochemistry34(34), 10872–10878 (1995).
  • Glomb MA , LangG. Isolation and characterization of glyoxal-arginine modifications.J. Agric. Food Chem.49(3), 1493–1501 (2001).
  • Rindgen D , NakajimaM, WehrliS, XuK, BlairIA. Covalent modifications to 2´-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation.Chem. Res. Toxicol.12(12), 1195–1204 (1999).
  • Lin D , LeeHG, LiuQ, PerryG, SmithMA, SayreLM. 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal.Chem. Res. Toxicol.18(8), 1219–1231 (2005).
  • Zhang WH , LiuJ, XuG, YuanQ, SayreLM. Model studies on protein side chain modification by 4-oxo-2-nonenal.Chem. Res. Toxicol.16(4), 512–523 (2003).
  • Zhu X , GalloglyMM, MieyalJJ, AndersonVE, SayreLM. Covalent cross-linking of glutathione and carnosine to proteins by 4-oxo-2-nonenal.Chem. Res. Toxicol.22(6), 1050–1059 (2009).
  • Brame CJ , SalomonRG, MorrowJD, RobertsLJ. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts.J. Biol. Chem.274(19), 13139–13146 (1999).
  • Davies SS , AmarnathV, RobertsLJ. Isoketals: highly reactive gamma-ketoaldehydes formed from the H2-isoprostane pathway.Chem. Phys. Lipids128(1–2), 85–99 (2004).
  • Brame CJ , BoutaudO, DaviesSSet al. Modification of proteins by isoketal-containing oxidized phospholipids. J. Biol. Chem. 279(14), 13447–13451 (2004).
  • Jackson B , BrockerC, ThompsonDCet al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum. Genomics 5(4), 283–303 (2011).
  • Pappa A , ChenC, KoutalosY, TownsendAJ, VasiliouV. Aldh3a1 protects human corneal epithelial cells from ultraviolet- and 4-hydroxy-2-nonenal-induced oxidative damage.Free Radic. Biol. Med.34(9), 1178–1189 (2003).
  • Townsend AJ , Leone-KablerS, HaynesRL, WuY, SzwedaL, BuntingKD. Selective protection by stably transfected human ALDH3A1 (but not human ALDH1A1) against toxicity of aliphatic aldehydes in V79 cells.Chem. Biol. Interact.130–132(1–3), 261–273 (2001).
  • Yoval-Sanchez B , Rodriguez-ZavalaJS. Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts.Chem. Res. Toxicol.25(3), 722–729 (2012).
  • Ramana KV . Aldose reductase. new insights for an old enzyme.Biomol. Concepts2(1–2), 103–114 (2011).
  • Pladzyk A , RamanaKV, AnsariNH, SrivastavaSK. Aldose reductase prevents aldehyde toxicity in cultured human lens epithelial cells.Exp. Eye Res.83(2), 408–416 (2006).
  • Srivastava SK , YadavUC, ReddyABet al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem. Biol. Interact. 191(1–3), 330–338 (2011).
  • Burczynski ME , SridharGR, PalackalNT, PenningTM. The reactive oxygen species – and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene.J. Biol. Chem.276(4), 2890–2897 (2001).
  • Gardner R , KaziS, EllisEM. Detoxication of the environmental pollutant acrolein by a rat liver aldo-keto reductase.Toxicol. Lett.148(1–2), 65–72 (2004).
  • Li D , FerrariM, EllisEM. Human aldo-keto reductase AKR7A2 protects against the cytotoxicity and mutagenicity of reactive aldehydes and lowers intracellular reactive oxygen species in hamster V79–4 cells.Chem. Biol. Interact.195(1), 25–34 (2012).
  • Sharma R , YangY, SharmaA, AwasthiS, AwasthiYC. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis.Antioxid. Redox. Signal.6(2), 289–300 (2004).
  • Pladzyk A , ReddyAB, YadavUC, TammaliR, RamanaKV, SrivastavaSK. Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells.Invest. Ophthalmol. Vis. Sci.47(12), 5395–5403 (2006).
  • Pamplona R . Membrane phospholipids, lipoxidative damage and molecular integrity: a causal role in aging and longevity.Biochim. Biophys. Acta1777(10), 1249–1262 (2008).
  • Voulgaridou GP , AnestopoulosI, FrancoR, PanayiotidisMI, PappaA. DNA damage induced by endogenous aldehydes: current state of knowledge.Mutat. Res.711(1–2), 13–27 (2011).
  • Aiello LP , GardnerTW, KingGLet al. Diabetic retinopathy. Diabetes Care 21(1), 143–156 (1998).
  • Klein R , KleinBE, MossSE. The Wisconsin epidemiological study of diabetic retinopathy: a review.Diabetes Metab. Rev.5(7), 559–570 (1989).
  • UK prospective diabetes study (UKPDS) group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352(9131), 837–853 (1998).
  • The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med.329(14), 977–986 (1993).
  • The diabetes control and complications trial research group. Hypoglycemia in the diabetes control and complications trial. Diabetes46(2), 271–286 (1997).
  • Gardiner TA , ArcherDB, CurtisTM, StittAW. Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis.Microcirculation14(1), 25–38 (2007).
  • Antonetti DA , BarberAJ, BronsonSKet al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 55(9), 2401–2411 (2006).
  • Hancock HA , KraftTW. Oscillatory potential analysis and ERGs of normal and diabetic rats.Invest. Ophthalmol. Vis. Sci.45(3), 1002–1008 (2004).
  • Phipps JA , YeeP, FletcherEL, VingrysAJ. Rod photoreceptor dysfunction in diabetes: activation, deactivation, and dark adaptation.Invest. Ophthalmol. Vis. Sci.47(7), 3187–3194 (2006).
  • Lieth E , BarberAJ, XuBet al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 47(5), 815–820 (1998).
  • Mizutani M , GerhardingerC, LorenziM. Muller cell changes in human diabetic retinopathy.Diabetes47(3), 445–449 (1998).
  • Rungger-Brandle E , DossoAA, LeuenbergerPM. Glial reactivity, an early feature of diabetic retinopathy.Invest. Ophthalmol. Vis. Sci.41(7), 1971–1980 (2000).
  • Hammes HP , BartmannA, EngelL, WulfrothP. Antioxidant treatment of experimental diabetic retinopathy in rats with nicanartine.Diabetologia40(6), 629–634 (1997).
  • Curtis TM , HamiltonR, YongPHet al. Muller glial dysfunction during diabetic retinopathy in rats is linked to accumulation of advanced glycation end-products and advanced lipoxidation end-products. Diabetologia 54(3), 690–698 (2011).
  • Bringmann A , PannickeT, GroscheJet al. Muller cells in the healthy and diseased retina. Prog. Retin. Eye Res. 25(4), 397–424 (2006).
  • Li Q , PuroDG. Diabetes-induced dysfunction of the glutamate transporter in retinal Müller cells.Invest. Ophthalmol. Vis. Sci.43(9), 3109–3116 (2002).
  • Pannicke T , IandievI, WurmAet al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 55(3), 633–639 (2006).
  • Gerhardinger C , CostaMB, CoulombeMC, TothI, HoehnT, GrosuP. Expression of acute-phase response proteins in retinal Muller cells in diabetes.Invest. Ophthalmol. Vis. Sci.46(1), 349–357 (2005).
  • Amin RH , FrankRN, KennedyA, EliottD, PuklinJE, AbramsGW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy.Invest. Ophthalmol. Vis. Sci.38(1), 36–47 (1997).
  • Inokuchi N , IkedaT, ImamuraYet al. Vitreous levels of insulin-like growth factor-I in patients with proliferative diabetic retinopathy. Curr. Eye Res. 23(5), 368–371 (2001).
  • Wang J , XuX, ElliottMH, ZhuM, LeYZ. Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage.Diabetes59(9), 2297–2305 (2010).
  • Miura J , YamagishiS, UchigataYet al. Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. J. Diabetes Complications 17(1), 16–21 (2003).
  • Wautier MP , MassinP, GuillausseauPJ et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in Type 2 diabetic patients. Diabetes Metab.29(1), 44–52 (2003).
  • Boehm BO , SchillingS, RosingerSet al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 47(8), 1376–1379 (2004).
  • Endo M , YanagisawaK, TsuchidaKet al. Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm. Metab. Res. 33(5), 317–322 (2001).
  • Genuth S , SunW, ClearyPet al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with Type 1 diabetes. Diabetes 54(11), 3103–3111 (2005).
  • Hammes HP , BrownleeM, LinJ, SchleicherE, BretzelRG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product N epsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia42(5), 603–607 (1999).
  • Stitt A , GardinerTA, AldersonNLet al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51(9), 2826–2832 (2002).
  • Losada M , AlioJL. Malondialdehyde serum concentration in Type 1 diabetic with and without retinopathy.Doc. Ophthalmol.93(3), 223–229 (1996).
  • Polak M , ZagorskiZ. Lipid peroxidation in diabetic retinopathy.Ann. Univ Mariae. Curie Sklodowska Med.59(1), 434–437 (2004).
  • Pan HZ , ZhangH, ChangD, LiH, SuiH. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy.Br. J. Ophthalmol.92(4), 548–551 (2008).
  • Grattagliano I , VendemialeG, BosciaF, Micelli-FerrariT, CardiaL, AltomareE. Oxidative retinal products and ocular damages in diabetic patients.Free Radic. Biol. Med.25(3), 369–372 (1998).
  • Baydas G , TuzcuM, YasarA, BaydasB. Early changes in glial reactivity and lipid peroxidation in diabetic rat retina: effects of melatonin.Acta Diabetol.41(3), 123–128 (2004).
  • Fathallah L , ObrosovaIG. Increased retinal lipid peroxidation in early diabetes is not associated with ascorbate depletion or changes in ascorbate redox state.Exp. Eye Res.72(6), 719–723 (2001).
  • Obrosova IG , FathallahL, GreeneDA. Early changes in lipid peroxidation and antioxidative defense in diabetic rat retina: effect of DL-alpha-lipoic acid. Eur. J. Pharmacol.398(1), 139–146 (2000).
  • Ali TK , MatragoonS, PillaiBA, LiouGI, El-RemessyAB. Peroxynitrite mediates retinal neurodegeneration by inhibiting nerve growth factor survival signaling in experimental and human diabetes.Diabetes57(4), 889–898 (2008).
  • Hartnett ME , StrattonRD, BrowneRW, RosnerBA, LanhamRJ, ArmstrongD. Serum markers of oxidative stress and severity of diabetic retinopathy.Diabetes Care23(2), 234–240 (2000).
  • Zhang X , LaiY, McCanceDRet al. Evaluation of N (epsilon)-(3-formyl-3,4-dehydropiperidino)lysine as a novel biomarker for the severity of diabetic retinopathy. Diabetologia 51(9), 1723–1730 (2008).
  • Yong PH , ZongH, MedinaRJet al. Evidence supporting a role for N-(3-formyl-3,4-dehydropiperidino)lysine accumulation in Muller glia dysfunction and death in diabetic retinopathy. Mol Vis 16, 2524–2538 (2010).
  • Pascolini D , MariottiSP. Global estimates of visual impairment: 2010.Br. J. Ophthalmol.96(5), 614–618 (2012).
  • Robman L , TaylorH. External factors in the development of cataract.Eye (Lond.)19(10), 1074–1082 (2005).
  • Stein JD . Serious adverse events after cataract surgery.Curr. Opin. Ophthalmol.23(3), 219–225 (2012).
  • Spector A . Oxidative stress-induced cataract: mechanism of action.FASEB J.9(12), 1173–1182 (1995).
  • Bhuyan KC , BhuyanDK, PodosSM. Lipid peroxidation in cataract of the human.Life Sci.38(16), 1463–1471 (1986).
  • Simonelli F , NestiA, PensaMet al. Lipid peroxidation and human cataractogenesis in diabetes and severe myopia. Exp. Eye Res. 49(2), 181–187 (1989).
  • Altomare E , VendemialeG, GrattaglianoI, AngeliniP, Micelli-FerrariT, CardiaL. Human diabetic cataract: role of lipid peroxidation.Diabetes Metab.21(3), 173–179 (1995).
  • Bhatia RP , RaiR, RaoGR. Role of malondialdehyde and superoxide dismutase in cataractogenesis.Ann. Ophthalmol.(Skokie.)38(2), 103–106 (2006).
  • Micelli-Ferrari T , VendemialeG, GrattaglianoIet al. Role of lipid peroxidation in the pathogenesis of myopic and senile cataract. Br. J. Ophthalmol. 80(9), 840–843 (1996).
  • Franke S , DawczynskiJ, StrobelJ, NiwaT, StahlP, SteinG. Increased levels of advanced glycation end products in human cataractous lenses.J. Cataract Refract. Surg.29(5), 998–1004 (2003).
  • Goosey JD , TuanWM, GarciaCA. A lipid peroxidative mechanism for posterior subcapsular cataract formation in the rabbit: a possible model for cataract formation in tapetoretinal diseases.Invest. Ophthalmol. Vis. Sci.25(5), 608–612 (1984).
  • Mibu H , NagataM, HikidaM. A study on lipid peroxide-induced lens damage in vitro. Exp. Eye Res.58(1), 85–90 (1994).
  • Ansari NH , WangL, SrivastavaSK. Role of lipid aldehydes in cataractogenesis: 4-hydroxynonenal-induced cataract.Biochem. Mol. Med.58(1), 25–30 (1996).
  • King G , HolmesR. Human ocular aldehyde dehydrogenase isozymes: distribution and properties as major soluble proteins in cornea and lens.J. Exp. Zool.282(1–2), 12–17 (1998).
  • Choudhary S , XiaoT, VergaraLAet al. Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress. Invest. Ophthalmol. Vis Sci. 46(1), 259–267 (2005).
  • Lassen N , BatemanJB, EsteyTet al. Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem. 282(35), 25668–25676 (2007).
  • Nees DW , WawrousekEF, RobisonWG Jr, Piatigorsky J. Structurally normal corneas in aldehyde dehydrogenase 3a1-deficient mice. Mol. Cell. Biol.22(3), 849–855 (2002).
  • Zigler JS Jr, Bodaness RS, Gery I, Kinoshita JH. Effects of lipid peroxidation products on the rat lens in organ culture: a possible mechanism of cataract initiation in retinal degenerative disease. Arch. Biochem. Biophys.225(1), 149–156 (1983).
  • LaVail MM . Legacy of the RCS rat: impact of a seminal study on retinal cell biology and retinal degenerative diseases.Prog. Brain Res.131, 617–627 (2001).
  • Zigler JS Jr, Hess HH. Cataracts in the Royal College of Surgeons rat: evidence for initiation by lipid peroxidation products. Exp. Eye Res.41(1), 67–76 (1985).
  • Jager RD , MielerWF, MillerJW. Age-related macular degeneration.N. Engl. J. Med.358(24), 2606–2617 (2008).
  • Abdelsalam A , DelPL, ZarbinMA. Drusen in age-related macular degeneration: pathogenesis, natural course, and laser photocoagulation-induced regression.Surv. Ophthalmol.44(1), 1–29 (1999).
  • de Jong PT . Age-related macular degeneration.N. Engl. J. Med.355(14), 1474–1485 (2006).
  • Grossniklaus HE , GreenWR. Choroidal neovascularization.Am. J. Ophthalmol.137(3), 496–503 (2004).
  • Kopitz J , HolzFG, KaemmererE, SchuttF. Lipids and lipid peroxidation products in the pathogenesis of age-related macular degeneration.Biochimie86(11), 825–831 (2004).
  • Schutt F , BergmannM, HolzFG, KopitzJ. Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium.Invest. Ophthalmol. Vis. Sci.44(8), 3663–3668 (2003).
  • Krohne TU , KaemmererE, HolzFG, KopitzJ. Lipid peroxidation products reduce lysosomal protease activities in human retinal pigment epithelial cells via two different mechanisms of action.Exp. Eye Res.90(2), 261–266 (2010).
  • Krohne TU , StratmannNK, KopitzJ, HolzFG. Effects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells.Exp. Eye Res.90(3), 465–471 (2010).
  • Krohne TU , HolzFG, KopitzJ. Apical-to-basolateral transcytosis of photoreceptor outer segments induced by lipid peroxidation products in human retinal pigment epithelial cells.Invest. Ophthalmol. Vis. Sci.51(1), 553–560 (2010).
  • Crabb JW , MiyagiM, GuXet al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA 99(23), 14682–14687 (2002).
  • Gu X , MeerSG, MiyagiMet al. Carboxyethylpyrrole protein adducts and autoantibodies, biomarkers for age-related macular degeneration. J. Biol. Chem. 278(43), 42027–42035 (2003).
  • Hollyfield JG , BonilhaVL, RaybornMEet al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nat. Med. 14(2), 194–198 (2008).
  • Ebrahem Q , RenganathanK, SearsJet al. Carboxyethylpyrrole oxidative protein modifications stimulate neovascularization: implications for age-related macular degeneration. Proc Natl. Acad. Sci. USA 103(36), 13480–13484 (2006).
  • Doyle SL , CampbellM, OzakiEet al. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat. Med. 18(5), 791–798 (2012).
  • DeAngelis MM , SilveiraAC, CarrEA, KimIK. Genetics of age-related macular degeneration: current concepts, future directions.Semin. Ophthalmol.26(3), 77–93 (2011).
  • Edwards AO , RitterR, III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science308(5720), 421–424 (2005).
  • Hageman GS , AndersonDH, JohnsonLVet al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. USA 102(20), 7227–7232 (2005).
  • Haines JL , HauserMA, SchmidtSet al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720), 419–421 (2005).
  • Klein RJ , ZeissC, ChewEYet al. Complement factor H polymorphism in age-related macular degeneration. Science 308(5720), 385–389 (2005).
  • Weismann D , HartvigsenK, LauerNet al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478(7367), 76–81 (2011).
  • Hartong DT , BersonEL, DryjaTP. Retinitis pigmentosa.Lancet368(9549), 1795–1809 (2006).
  • Punzo C , XiongW, CepkoCL. Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame?J. Biol. Chem.287(3), 1642–1648 (2012).
  • Yu DY , CringleS, ValterK, WalshN, LeeD, StoneJ. Photoreceptor death, trophic factor expression, retinal oxygen status, and photoreceptor function in the P23H rat.Invest. Ophthalmol. Vis. Sci.45(6), 2013–2019 (2004).
  • Shen J , YangX, DongAet al. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J. Cell. Physiol. 203(3), 457–464 (2005).
  • Komeima K , RogersBS, LuL, CampochiaroPA. Antioxidants reduce cone cell death in a model of retinitis pigmentosa.Proc. Natl Acad. Sci. USA103(30), 11300–11305 (2006).
  • Schock BC , SweetDG, HallidayHL, YoungIS, EnnisM. Oxidative stress in lavage fluid of preterm infants at risk of chronic lung disease.Am. J. Physiol. Lung Cell. Mol. Physiol.281(6), L1386–L1391 (2001).
  • Sapieha P , JoyalJS, RiveraJCet al. Retinopathy of prematurity: understanding ischemic retinal vasculopathies at an extreme of life. J. Clin. Invest. 120(9), 3022–3032 (2010).
  • Lutty GA , Chan-LingT, PhelpsDLet al. Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California). Mol. Vis. 12, 532–580 (2006).
  • Weinberger B , AnwarM, HenienSet al. Association of lipid peroxidation with antenatal betamethasone and oxygen radial disorders in preterm infants. Biol. Neonate 85(2), 121–127 (2004).
  • Tsukahara H , JiangMZ, OhtaNet al. Oxidative stress in neonates: evaluation using specific biomarkers. Life Sci. 75(8), 933–938 (2004).
  • Quigley HA . Glaucoma.Lancet377(9774), 1367–1377 (2011).
  • Almasieh M , WilsonAM, MorquetteB, Cueva Vargas JL, Di PA. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res.31(2), 152–181 (2012).
  • Ghanem AA , ArafaLF, El-BazA. Oxidative stress markers in patients with primary open-angle glaucoma.Curr. Eye Res.35(4), 295–301 (2010).
  • Chang D , ShaQ, ZhangXet al. The evaluation of the oxidative stress parameters in patients with primary angle-closure glaucoma. PLoS. ONE 6(11), e27218 (2011).
  • Liu Q , JuWK, CrowstonJGet al. Oxidative stress is an early event in hydrostatic pressure induced retinal ganglion cell damage. Invest. Ophthalmol. Vis. Sci. 48(10), 4580–4589 (2007).
  • Ju WK , LiuQ, KimKYet al. Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest. Ophthalmol. Vis. Sci. 48(5), 2145–2151 (2007).
  • Yadav UC , KalariyaNM, RamanaKV. Emerging role of antioxidants in the protection of uveitis complications.Curr. Med. Chem.18(6), 931–942 (2011).
  • Rosenbaum JT , McDevittHO, GussRB, EgbertPR. Endotoxin-induced uveitis in rats as a model for human disease.Nature286(5773), 611–613 (1980).
  • Rao NA . Role of oxygen free radicals in retinal damage associated with experimental uveitis.Trans. Am. Ophthalmol. Soc.88, 797–850 (1990).
  • Ishimoto S , WuGS, HayashiS, ZhangJ, RaoNA. Free radical tissue damages in the anterior segment of the eye in experimental autoimmune uveitis.Invest. Ophthalmol. Vis. Sci.37(4), 630–636 (1996).
  • Satici A , GuzeyM, GurlerB, VuralH, GurkanT. Malondialdehyde and antioxidant enzyme levels in the aqueous humor of rabbits in endotoxin-induced uveitis.Eur. J. Ophthalmol.13(9–10), 779–783 (2003).
  • Yadav UC , SrivastavaSK, RamanaKV. Understanding the role of aldose reductase in ocular inflammation.Curr. Mol. Med.10(6), 540–549 (2010).
  • Yadav UC , ShoebM, SrivastavaSK, RamanaKV. Aldose reductase deficiency protects from autoimmune- and endotoxin-induced uveitis in mice.Invest. Ophthalmol. Vis. Sci.52(11), 8076–8085 (2011).
  • Yadav UC , SrivastavaSK, RamanaKV. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats.Invest. Ophthalmol. Vis. Sci.48(10), 4634–4642 (2007).
  • Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol.119(10), 1417–1436 (2001).
  • Kowluru RA , ChanPS. Oxidative stress and diabetic retinopathy.Exp. Diabetes Res.2007, 43603 (2007).
  • Kowluru RA , KanwarM, ChanPS, ZhangJP. Inhibition of retinopathy and retinal metabolic abnormalities in diabetic rats with AREDS-based micronutrients.Arch. Ophthalmol.126(9), 1266–1272 (2008).
  • Millen AE , GruberM, KleinR, KleinBE, PaltaM, MaresJA. Relations of serum ascorbic acid and alpha-tocopherol to diabetic retinopathy in the Third National Health and Nutrition Examination Survey.Am. J. Epidemiol.158(3), 225–233 (2003).
  • Garcia-Medina JJ , Pinazo-DuranMD, Garcia-MedinaM, Zanon-MorenoV, Pons-VazquezS. A 5-year follow-up of antioxidant supplementation in Type 2 diabetic retinopathy.Eur. J. Ophthalmol.21(5), 637–643 (2011).
  • Pasantes-Morales H , QuirozH, QuesadaO. Treatment with taurine, diltiazem, and vitamin E retards the progressive visual field reduction in retinitis pigmentosa: a 3-year follow-up study.Metab. Brain Dis.17(3), 183–197 (2002).
  • Motohashi H , YamamotoM. Nrf2-Keap1 defines a physiologically important stress response mechanism.Trends Mol. Med.10(11), 549–557 (2004).
  • Ellis EM . Reactive carbonyls and oxidative stress: potential for therapeutic intervention.Pharmacol. Ther.115(1), 13–24 (2007).
  • Gao X , TalalayP. Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage.Proc. Natl. Acad. Sci. USA101(28), 10446–10451 (2004).
  • Kong L , TanitoM, HuangZet al. Delay of photoreceptor degeneration in tubby mouse by sulforaphane. J. Neurochem. 101(4), 1041–1052 (2007).
  • Xue M , QianQ, AdaikalakoteswariA, RabbaniN, Babaei-JadidiR, ThornalleyPJ. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease.Diabetes57(10), 2809–2817 (2008).
  • Zheng H , WhitmanSA, WuWet al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60(11), 3055–3066 (2011).
  • Feng Z , LiuZ, LiXet al. Alpha-Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells. J. Nutr. Biochem. 21(12), 1222–1231 (2010).
  • Zhu L , LiuZ, FengZet al. Hydroxytyrosol protects against oxidative damage by simultaneous activation of mitochondrial biogenesis and phase II detoxifying enzyme systems in retinal pigment epithelial cells. J. Nutr. Biochem. 21(11), 1089–1098 (2010).
  • Dorr RT . Chemoprotectants for cancer chemotherapy.Semin. Oncol.18(1, Suppl. 2), 48–58 (1991).
  • Burcham PC , KaminskasLM, TanD, PykeSM. Carbonyl-scavenging drugs and protection against carbonyl stress-associated cell injury.Mini. Rev. Med. Chem.8(4), 319–330 (2008).
  • Hammes HP , MartinS, FederlinK, GeisenK, BrownleeM. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy.Proc. Natl Acad. Sci. USA88(24), 11555–11558 (1991).
  • Lewis BS , HardingJJ. The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins.Exp. Eye Res.50(5), 463–467 (1990).
  • Burcham PC , KaminskasLM, FontaineFR, PetersenDR, PykeSM. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products.Toxicology181–182, 229–236 (2002).
  • Ihm SH , YooHJ, ParkSW, IhmJ. Effect of aminoguanidine on lipid peroxidation in streptozotocin-induced diabetic rats.Metabolism48(9), 1141–1145 (1999).
  • Zheng L , DuY, MillerCet al. Critical role of inducible nitric oxide synthase in degeneration of retinal capillaries in mice with streptozotocin-induced diabetes. Diabetologia 50(9), 1987–1996 (2007).
  • Takano K , OguraM, YonedaY, NakamuraY. Oxidative metabolites are involved in polyamine-induced microglial cell death.Neuroscience134(4), 1123–1131 (2005).
  • Freedman BI , WuerthJP, CartwrightKet al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control. Clin. Trials 20(5), 493–510 (1999).
  • Osicka TM , YuY, LeeV, PanagiotopoulosS, KempBE, JerumsG. Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.Clin. Sci.(Lond.)100(3), 249–257 (2001).
  • Thornalley PJ . Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts.Arch. Biochem. Biophys.419(1), 31–40 (2003).
  • Metz TO , AldersonNL, ThorpeSR, BaynesJW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.Arch. Biochem. Biophys.419(1), 41–49 (2003).
  • Voziyan PA , MetzTO, BaynesJW, HudsonBG. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation.J. Biol. Chem.277(5), 3397–3403 (2002).
  • Kang Z , LiH, LiG, YinD. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.Amino Acids30(1), 55–61 (2006).
  • Amarnath V , AmarnathK, AmarnathK, DaviesS, RobertsLJ. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls.Chem. Res. Toxicol.17(3), 410–415 (2004).
  • Voziyan PA , HudsonBG. Pyridoxamine: the many virtues of a maillard reaction inhibitor.Ann. NY Acad. Sci.1043, 807–816 (2005).
  • Aldini G , FacinoRM, BerettaG, CariniM. Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives.Biofactors24(1–4), 77–87 (2005).
  • Shi Q , YanH, LiMY, HardingJJ. Effect of a combination of carnosine and aspirin eye drops on streptozotocin – induced diabetic cataract in rats.Mol. Vis.15, 2129–2138 (2009).
  • Babizhayev MA . Current ocular drug delivery challenges for N-acetylcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships. Recent Pat. Drug Deliv. Formul.3(3), 229–265 (2009).
  • Pfister F , RiedlE, WangQet al. Oral carnosine supplementation prevents vascular damage in experimental diabetic retinopathy. Cell. Physiol. Biochem. 28(1), 125–136 (2011).
  • Burcham PC , KerrPG, FontaineF. The antihypertensive hydralazine is an efficient scavenger of acrolein.Redox. Rep.5(1), 47–49 (2000).
  • Burcham PC , FontaineFR, KaminskasLM, PetersenDR, PykeSM. Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity.Mol. Pharmacol.65(3), 655–664 (2004).
  • Kaminskas LM , PykeSM, BurchamPC. Strong protein adduct trapping accompanies abolition of acrolein-mediated hepatotoxicity by hydralazine in mice.J. Pharmacol. Exp. Ther.310(3), 1003–1010 (2004).
  • Kaminskas LM , PykeSM, BurchamPC. Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde.Org. Biomol. Chem.2(18), 2578–2584 (2004).
  • Druey J , MarxerA. Hypotensive Hydrazinophthalazines and Related Compounds.J. Med. Pharm. Chem.1(1), 1–21 (1959).
  • Reinhardt DJ , WaldronJM. Lupus erythematosus-like syndrome complicating hydralazine (apresoline) therapy.J. Am. Med. Assoc.155(17), 1491–1492 (1954).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.